PMV Pharmaceuticals entered into an underwriting agreement with TD Securities for a public offering of common stock, pre-funded warrants, and accompanying warrants. The company sold 22,055,000 shares and pre-funded warrants for up to 19,900,000 additional shares, paired with warrants for 41,955,000 shares. Gross proceeds are approximately $50.8 million, yielding net proceeds of about $47.0 million after fees. The offering priced at $1.21 per share and warrant package, with closing expected September 2, 2026. Funds will support late-stage clinical development and commercialization preparation for rezatapopt, a therapy targeting p53 mutations in ovarian cancer. PMV Pharmaceuticals is a precision oncology company developing small molecule therapies.

PMV Pharmaceuticals announced updated interim data from the Phase 2 pivotal PYNNACLE trial for its p53 reactivator rezatapopt in platinum-resistant/refractory ovarian cancer. Among 76 evaluable patients, the drug demonstrated a 46% overall response rate with a median duration of response of 10.0 months and a favorable safety profile. The company received FDA feedback supporting a New Drug Application strategy for accelerated approval, with submission planned for the first quarter of 2027. PMV Pharmaceuticals is a precision oncology company developing small molecule therapies targeting p53 mutations.

PMV Pharmaceuticals reported second quarter 2026 financial results on August 14, 2026. The company ended the quarter with $79.4 million in cash and marketable securities, down from $112.9 million at year-end 2025. Net loss for the quarter was $18.1 million, compared to $21.2 million in the prior-year period, driven by lower contract research organization costs. Research and development expenses decreased to $14.7 million from $18.4 million. Clinically, enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE trial has been completed. The company plans to submit a New Drug Application (NDA) for accelerated approval of rezatapopt for this indication in the first quarter of 2027, with an expected cash runway through the second quarter of 2027. PMV Pharmaceuticals is a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53.